학술논문

The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB)
Document Type
article
Source
Alzheimer's & Dementia. 20(1)
Subject
Biomedical and Clinical Sciences
Biological Psychology
Clinical Sciences
Neurosciences
Psychology
Alzheimer's Disease
Neurodegenerative
Dementia
Acquired Cognitive Impairment
Aging
Brain Disorders
Biomedical Imaging
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Neurological
Humans
Alzheimer Disease
Neuroimaging
Biomedical Research
Biomarkers
Blood Coagulation Factors
Alzheimer's disease clinical trials
Alzheimer's Disease Neuroimaging Initiative
biomarkers
neuroimaging
Geriatrics
Clinical sciences
Biological psychology
Language
Abstract
The Alzheimer's Disease Neuroimaging Initiative (ADNI) Private Partners Scientific Board (PPSB) encompasses members from industry, biotechnology, diagnostic, and non-profit organizations that have until recently been managed by the Foundation for the National Institutes of Health (FNIH) and provided financial and scientific support to ADNI programs. In this article, we review some of the major activities undertaken by the PPSB, focusing on those supporting the most recently completed National Institute on Aging grant, ADNI3, and the impact it has had on streamlining biomarker discovery and validation in Alzheimer's disease. We also provide a perspective on the gaps that may be filled with future PPSB activities as part of ADNI4 and beyond. HIGHLIGHTS: The Private Partners Scientific board (PPSB) continues to play a key role in enabling several Alzheimer's Disease Neuroimaging Initiative (ADNI) activities. PPSB working groups have led landscape assessments to provide valuable feedback on new technologies, platforms, and methods that may be taken up by ADNI in current or future iterations.